{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:19:32Z","timestamp":1785151172688,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,18]],"date-time":"2008-01-18T00:00:00Z","timestamp":1200614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> It is claimed that second generation thyrotropin\u2010binding inhibitory immunoglobulin (TBII) assays have a very high sensitivity for the diagnosis of Graves\u2019 hyperthyroidism (GH). However, studies evaluating the accuracy of TBII have been retrospective in nature and\/or GH had not been diagnosed independently of TBII. The aim of the present study, therefore, was to prospectively evaluate the frequency and characteristics of TBII\u2010seronegative patients in a population of untreated GH diagnosed independent of serum TBII.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> Prospective multicentre observational study.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> A total of 259 consecutive untreated patients with a first episode of GH, diagnosed independent of serum TBII. TBII levels were measured by second generation assay and correlated to thyroid function, clinical characteristics and exposure to environmental factors.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Serum TBII was positive in 245 (94\u00b76%) patients and negative (&lt;\u00a02\u00a0IU\/l) in 14 (5\u00b74%) patients. TBII\u2010seronegative patients had lower fT4 (median 42\u00b75 <jats:italic>vs.<\/jats:italic> 53\u00b79\u00a0pmol\/l, <jats:italic>P<\/jats:italic>\u00a0=\u00a00\u00b702), T3 (median 3\u00b755 <jats:italic>vs.<\/jats:italic> 4\u00b790\u00a0nmol\/l, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701) and fT3\u2010index (median 4\u00b730 <jats:italic>vs.<\/jats:italic> 6\u00b727, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00\u00b701) compared to TBII\u2010seropositive patients. None of the TBII\u2010seronegative patients had TSH\u2010receptor activating mutations, Graves\u2019 orbitopathy or pretibial myxedema. Serum TBII was positively correlated to free T3 (fT3)\u2010index and free T4 (fT4)\u2010index (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b701), goitre size (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b701) and the prevalence of Graves\u2019 orbitopathy (<jats:italic>P\u00a0&lt;<\/jats:italic>\u00a00\u00b701). There were no significant differences between TBII\u2010seropositive and TBII\u2010seronegative patients in environmental factors.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> The prevalence of TBII\u2010seronegativity in untreated patients with GH is 5\u00b74% using a second generation assay. TBII\u2010seronegative patients have biochemically less severe thyrotoxicosis and no Graves\u2019 orbitopathy. TBII\u2010seronegative and TBII\u2010seropositive patients apparently belong to the same population of GH, albeit the severity of the autoimmune attack is less in TBII\u2010seronegative patients.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2008.03192.x","type":"journal-article","created":{"date-parts":[[2008,2,13]],"date-time":"2008-02-13T10:40:50Z","timestamp":1202899250000},"page":"311-317","source":"Crossref","is-referenced-by-count":70,"title":["Frequency and characteristics of TBII\u2010seronegative patients in a population with untreated Graves\u2019 hyperthyroidism: a prospective study"],"prefix":"10.1111","volume":"69","author":[{"given":"Xander G.","family":"Vos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Endert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan G. P.","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmar M.","family":"Wiersinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.930"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01894.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1402"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.3.4624"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.951"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1440595"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1982.tb01607.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.1.90"},{"key":"e_1_2_6_10_2","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1093\/clinchem\/32.7.1332","article-title":"Assays for thyrotropin\u2010receptor binding and thyroid\u2010stimulating antibodies in sera from patients with Graves\u2019 disease","volume":"32","author":"Massart C.","year":"1986","journal-title":"Clinical Chemistry"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01347.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-924979"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2001.007"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.2986"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1500605"},{"key":"e_1_2_6_16_2","first-page":"369","article-title":"Technique of endemic goitre surveys","volume":"44","author":"Perez C.","year":"1960","journal-title":"Monographic Series of World Health Organization"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/archinte.1988.00380020131018","article-title":"Symptom rating scale for assessing hyperthyroidism","volume":"148","author":"Klein I.","year":"1988","journal-title":"Archives of Internal Medicine"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(82)84024-X"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.16.295"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2001.01197.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978666"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.012294"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02471.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2813"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2000.00959.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1999.9.1175"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.809"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200506050-00003"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.3"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03344971"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1974.tb01811.x"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-1-26"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61762-2"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2008.03192.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2008.03192.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:19:37Z","timestamp":1697228377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2008.03192.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,15]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1365-2265.2008.03192.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03192.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,15]]}}}